Arcutis Biotherapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Arcutis Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $34.63. The average 1-year stock price forecast is 40.20% higher than the current stock price, while the lowest is $33 (+33.60%) and the highest is $36 (+45.75%).

Price Target: $34.63 (+40.20%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$33	$34.63	$35	$36
Change	+33.60%	+40.20%	+41.70%	+45.75%

Analyst Ratings

The average analyst rating for Arcutis Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	5	5	5	5	5	5
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Uy Ear Mizuho Securities	Mizuho Securities	Buy Reiterates $35	Buy	Reiterates	$35	+41.70%	Jun 3, 2026
Seamus Fernandez Guggenheim	Guggenheim	Buy Maintains $35	Buy	Maintains	$35	+41.70%	May 26, 2026
Douglas Tsao H.C. Wainwright	H.C. Wainwright	Buy Reiterates $34	Buy	Reiterates	$34	+37.65%	May 11, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Maintains $35 → $34	Buy	Maintains	$35 → $34	+37.65%	May 7, 2026
Tyler Van Buren TD Cowen	TD Cowen	Buy Maintains $35	Buy	Maintains	$35	+41.70%	May 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

497.11M

from 376.07M

32.19%

from 376.07M

Revenue Next Year

645.81M

from 497.11M

29.91%

from 497.11M

EPS This Year

0.17

from -0.13

EPS Next Year

1.13

from 0.17

582.83%

from 0.17

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	3.69M	59.61M	196.54M	376.07M	497.11M
Revenue Growth	-	-	1,517.09%	229.74%	91.34%	32.19%
Gross Profit	-	2.93M	54.62M	177.41M	339.38M	449.89M
Gross Margin	-	79.54%	91.63%	90.27%	90.24%	90.50%
Operating Income	-206.53M	-301.63M	-241.10M	-128.40M	-12.23M	22.28M
Net Income	-206.36M	-311.46M	-262.14M	-140.04M	-16.14M	15.18M
EPS	-	-	-	-	-0.13	0.17
Forward PE	-	-	-	-	76.62	149.70
Free Cash Flow	-102.77M	-195.81M	-152.09M	-72.90M	-15.70M	44.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	501.3M
Avg	497.1M
Low	490.6M

Revenue Growth

Revenue Growth	2026	2027	2028
High	33.3%
Avg	32.2%
Low	30.5%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	0.17
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-